Hyloris Raises €80m For Business Development

Company Anticipates First European Approval

 
• By Akriti Seth

With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.

Speech_Bubble_Funding
After launching its initial public offering, the Belgian value-added medicine specialist successfully raises €80m through public listing. • Source: Shutterstock

More from Earnings

More from Business